European Biotech Is “Hot” Again, But Needs Nurturing For Further Growth
European biotech executives, entrepreneurs and investors are much more optimistic today about the sector’s growth prospects than just a few years ago – that’s despite lingering negatives like the region’s small number of mid-sized companies, a lack of investors willing to finance beyond seed and Series A rounds, and the relative dearth of executive talent.
You may also be interested in...
The Fremont, California-based company has developed a computer-driven discovery platform that can model drug-protein interactions with unparalleled accuracy but can also generate synthetic pathways for its drug candidates.
Three product launches in U.S. last year, including Entyvio, showcase its expansion strategy, but first non-Japanese CEO could be biggest shift for firm.
Since 2013, investors have rallied around biotech IPOs like never before. START-UP looks at the current window and the implications of investor enthusiasm for newly public companies.